breast neoplasms

Summary

Summary: Tumors or cancer of the human BREAST.

Top Publications

  1. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  2. ncbi A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
  3. ncbi A pathway-based classification of human breast cancer
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:6994-9. 2010
  4. ncbi Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
  5. ncbi The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
    Philip A Gregory
    Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Nat Cell Biol 10:593-601. 2008
  6. ncbi Involvement of chemokine receptors in breast cancer metastasis
    A Muller
    Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
    Nature 410:50-6. 2001
  7. ncbi ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
  8. ncbi Genes that mediate breast cancer metastasis to lung
    Andy J Minn
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 436:518-24. 2005
  9. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
  10. ncbi MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005

Research Grants

  1. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2007
  2. CELLULAR MECHANISMS IN THE INDUCTION OF AROMATASE
    CAROLE MENDELSON; Fiscal Year: 2009
  3. Dissecting the Mechanisms of Tamoxifen Action
    Manohar Ratnam; Fiscal Year: 2009
  4. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
  5. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2009
  6. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2007
  7. Molecular Epidemiology of Secondary Lung Cancer
    Peter Shields; Fiscal Year: 2007
  8. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2005
  9. Protein-DNA Drug Carriers for Tumor Targeting
    Lali K Medina Kauwe; Fiscal Year: 2010
  10. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John Katzenellenbogen; Fiscal Year: 2007

Detail Information

Publications224 found, 100 shown here

  1. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  2. ncbi A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
    ..We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations...
  3. ncbi A pathway-based classification of human breast cancer
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:6994-9. 2010
    ..We propose that this classification scheme provides a basis for understanding the complex mechanisms of oncogenesis that give rise to these tumors and to identify rational opportunities for combination therapies...
  4. ncbi Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
    ..Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies...
  5. ncbi The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
    Philip A Gregory
    Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Nat Cell Biol 10:593-601. 2008
    ..Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression...
  6. ncbi Involvement of chemokine receptors in breast cancer metastasis
    A Muller
    Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
    Nature 410:50-6. 2001
    ..Our findings indicate that chemokines and their receptors have a critical role in determining the metastatic destination of tumour cells...
  7. ncbi ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  8. ncbi Genes that mediate breast cancer metastasis to lung
    Andy J Minn
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 436:518-24. 2005
    ..Others contribute to aggressive growth selectively in the lung. Many encode extracellular proteins and are of previously unknown relevance to cancer metastasis...
  9. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
    ..CONCLUSIONS: The gene-expression profile we studied is a more powerful predictor of the outcome of disease in young patients with breast cancer than standard systems based on clinical and histologic criteria...
  10. ncbi MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005
    ..We could identify miRNAs whose expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index...
  11. ncbi Gene expression profiling predicts clinical outcome of breast cancer
    Laura J van 't Veer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
    Nature 415:530-6. 2002
    ..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
  12. ncbi Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
    Jing Yang
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell 117:927-39. 2004
    ..These results establish a mechanistic link between Twist, EMT, and tumor metastasis...
  13. ncbi Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    Sohrab P Shah
    Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver V5Z 1L3, Canada
    Nature 461:809-13. 2009
    ..Taken together, our data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression...
  14. ncbi An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
    Ittai Ben-Porath
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA
    Nat Genet 40:499-507. 2008
    ....
  15. ncbi Genome remodelling in a basal-like breast cancer metastasis and xenograft
    Li Ding
    The Genome Center at Washington University, St Louis, Missouri 63108, USA
    Nature 464:999-1005. 2010
    ..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour...
  16. ncbi Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
    ..The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development...
  17. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  18. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  19. ncbi Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
    Elgene Lim
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Nat Med 15:907-13. 2009
    ..Our findings suggest that an aberrant luminal progenitor population is a target for transformation in BRCA1-associated basal tumors ...
  20. ncbi Triple-negative breast cancer
    William D Foulkes
    Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada
    N Engl J Med 363:1938-48. 2010
    ..This review focuses on its origin, molecular and clinical characteristics, and treatment...
  21. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ..The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options...
  22. ncbi Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
    Joseph H Taube
    Department of Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    Proc Natl Acad Sci U S A 107:15449-54. 2010
    ..Additionally, the expression level of FOXC1, another EMT inducer, correlates strongly with poor survival of breast cancer patients...
  23. ncbi Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells
    Yohei Shimono
    Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, CA 94304, USA
    Cell 138:592-603. 2009
    ..The coordinated downregulation of three microRNA clusters and the similar functional regulation of clonal expansion by miR-200c provide a molecular link that connects BCSCs with normal stem cells...
  24. ncbi A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis
    Scott Valastyan
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 137:1032-46. 2009
    ..Indeed, RhoA re-expression partially reverses miR-31-imposed metastasis suppression. These findings indicate that miR-31 uses multiple mechanisms to oppose metastasis...
  25. ncbi Association of reactive oxygen species levels and radioresistance in cancer stem cells
    Maximilian Diehn
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 458:780-3. 2009
    ....
  26. ncbi Endogenous human microRNAs that suppress breast cancer metastasis
    Sohail F Tavazoie
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 451:147-52. 2008
    ..miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer...
  27. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
    ..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
  28. ncbi let-7 regulates self renewal and tumorigenicity of breast cancer cells
    Fengyan Yu
    Department of Breast Surgery, No 2 Affiliated Hospital, Sun Yat Sen University, Guangzhou 510120, People s Republic of China
    Cell 131:1109-23. 2007
    ..Therefore let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target...
  29. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  30. ncbi Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
    ..The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm...
  31. ncbi A multigenic program mediating breast cancer metastasis to bone
    Yibin Kang
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Cell 3:537-49. 2003
    ....
  32. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  33. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA and the College of American Pathologists, Northfield, IL, USA
    Arch Pathol Lab Med 131:18-43. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2(HER2) testing in invasive breast cancer and its utility as a predictive marker...
  34. ncbi Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  35. ncbi Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Charles L Vogel
    University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
    J Clin Oncol 20:719-26. 2002
    ..CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH...
  36. ncbi miR-21-mediated tumor growth
    M L Si
    Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    Oncogene 26:2799-803. 2007
    ..Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target...
  37. ncbi Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
    Jason I Herschkowitz
    Lineberger Comprehensive Cancer Center
    Genome Biol 8:R76. 2007
    ..To address this need, we characterized mammary tumor gene expression profiles from 13 different murine models using DNA microarrays and compared the resulting data to those from human breast tumors...
  38. ncbi The genomic landscapes of human breast and colorectal cancers
    Laura D Wood
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 318:1108-13. 2007
    ..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
  39. ncbi Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    N Engl J Med 347:1233-41. 2002
    ..In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer...
  40. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  41. ncbi Metastatic behavior of breast cancer subtypes
    Hagen Kennecke
    Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:3271-7. 2010
    ..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
  42. ncbi Induction of autophagy and inhibition of tumorigenesis by beclin 1
    X H Liang
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nature 402:672-6. 1999
    ..These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies...
  43. ncbi The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
    Tiffany M Phillips
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-1714, USA
    J Natl Cancer Inst 98:1777-85. 2006
    ..These findings offer a possible mechanism for the accelerated repopulation of tumor cells observed during gaps in radiotherapy...
  44. ncbi Multidrug resistance in cancer: role of ATP-dependent transporters
    Michael M Gottesman
    Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 2:48-58. 2002
    ..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
  45. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  46. ncbi The consensus coding sequences of human breast and colorectal cancers
    Tobias Sjoblom
    Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Science 314:268-74. 2006
    ..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology...
  47. ncbi Supervised risk predictor of breast cancer based on intrinsic subtypes
    Joel S Parker
    Lineberger Comprehensive Cancer Center, Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 27:1160-7. 2009
    ..The prognostic properties of the continuous risk score will be of value for the management of node-negative breast cancers. The subtypes and risk score can also be used to assess the likelihood of efficacy from neoadjuvant chemotherapy...
  48. ncbi A systems biology approach for pathway level analysis
    Sorin Draghici
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48202, USA
    Genome Res 17:1537-45. 2007
    ..This analysis method has been implemented as a Web-based tool, Pathway-Express, freely available as part of the Onto-Tools (http://vortex.cs.wayne.edu)...
  49. ncbi Stromal gene expression predicts clinical outcome in breast cancer
    Greg Finak
    McGill Centre for Bioinformatics, 3775 University Street, McGill University, Quebec H3A 2B4, Canada
    Nat Med 14:518-27. 2008
    ..Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression...
  50. ncbi PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    J Li
    Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
    Science 275:1943-7. 1997
    ..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
  51. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients)...
  52. ncbi Genome-wide association study identifies five new breast cancer susceptibility loci
    Clare Turnbull
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 42:504-7. 2010
    ....
  53. ncbi Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
    Chad J Creighton
    Department of Molecular and Cellular Biology, Division of Biostatistics, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 106:13820-5. 2009
    ..Targeting proteins involved in EMT may provide a therapeutic strategy for eliminating surviving cells to prevent recurrence and improve long-term survival in breast cancer patients...
  54. ncbi Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Jayanta Debnath
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Methods 30:256-68. 2003
    ....
  55. ncbi Systemic spread is an early step in breast cancer
    Yves Hüsemann
    Department of Pathology, Division of Oncogenomics, University of Regensburg, Regensburg 93053, Germany
    Cancer Cell 13:58-68. 2008
    ..Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis...
  56. ncbi Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
    ....
  57. ncbi Genes that mediate breast cancer metastasis to the brain
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 459:1005-9. 2009
    ..This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions...
  58. ncbi Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  59. ncbi American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    J Clin Oncol 28:2784-95. 2010
    ..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
  60. ncbi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  61. ncbi Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
    Xiaoxian Li
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
    J Natl Cancer Inst 100:672-9. 2008
    ....
  62. ncbi Repeated observation of breast tumor subtypes in independent gene expression data sets
    Therese Sorlie
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:8418-23. 2003
    ..Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities...
  63. ncbi Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs
    Luigi Cicatiello
    Department of General Pathology, Second University of Naples, Napoli, Italy
    Am J Pathol 176:2113-30. 2010
    ....
  64. ncbi MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)
    Shuomin Zhu
    Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    J Biol Chem 282:14328-36. 2007
    ..Thus, down-regulation of TPM1 by mir-21 may explain, at least in part, why suppression of mir-21 can inhibit tumor growth, further supporting the notion that mir-21 functions as an oncogene...
  65. ncbi Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
    Anna V Ivshina
    Genome Institute of Singapore, Singapore
    Cancer Res 66:10292-301. 2006
    ....
  66. ncbi Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations
    Guido Sauter
    Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
    J Clin Oncol 27:1323-33. 2009
    ..Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2-targeted therapies...
  67. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients...
  68. ncbi Circulating microRNAs as novel minimally invasive biomarkers for breast cancer
    Helen M Heneghan
    Department of Surgery, National University of Ireland, Galway, Ireland
    Ann Surg 251:499-505. 2010
    ..The objective of this study was to investigate the potential of circulating microRNAs as novel breast cancer biomarkers...
  69. ncbi A microRNA signature of hypoxia
    Ritu Kulshreshtha
    Molecular Oncology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Mol Cell Biol 27:1859-67. 2007
    ..Interestingly, the vast majority of hypoxia-induced microRNAs are also overexpressed in a variety of human tumors...
  70. ncbi Breast cancer as a global health concern
    Steven S Coughlin
    Environmental Epidemiology Service, Office of Public Health and Environmental Hazards, Department of Veterans Affairs, Washington, DC, USA
    Cancer Epidemiol 33:315-8. 2009
    ..Additional data are needed for various geographic areas to assess resources required, cost-effectiveness, and humane approaches for preventing or controlling breast cancer in low resource settings in developing countries...
  71. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  72. ncbi Basal-like breast cancer: a critical review
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital National Health Service NHS Trust, UK
    J Clin Oncol 26:2568-81. 2008
    ..In this review, we discuss definition, heterogeneity, morphologic spectrum, relation to BRCA1, and clinical significance of this important class of breast cancer...
  73. ncbi BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
    Gemma Molyneux
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Cell Stem Cell 7:403-17. 2010
    ..They also demonstrate that when target cells for transformation have the potential for phenotypic plasticity, tumor phenotypes may not directly reflect histogenesis. This has important implications for cancer prevention strategies...
  74. ncbi A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
    Pierre Farmer
    Swiss National Centre of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Federale de Lausanne, School of Life Sciences, Epalinges s Lausanne, Switzerland
    Nat Med 15:68-74. 2009
    ..These findings identify a previously undescribed resistance mechanism to FEC treatment and suggest that antistromal agents may offer new ways to overcome resistance to chemotherapy...
  75. ncbi EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
    ..This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation...
  76. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  77. ncbi HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    E Laughner
    Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914, USA
    Mol Cell Biol 21:3995-4004. 2001
    ..These data provide a molecular basis for VEGF induction and tumor angiogenesis by heregulin-HER2 signaling and establish a novel mechanism for the regulation of HIF-1alpha expression...
  78. ncbi The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006
    ..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list...
  79. ncbi Deconstructing the molecular portraits of breast cancer
    Aleix Prat
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Mol Oncol 5:5-23. 2011
    ....
  80. ncbi Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery
    Jessica Kao
    Department of Pathology, Stanford University, Stanford, CA, USA
    PLoS ONE 4:e6146. 2009
    ..Here, we studied a collection of breast cancer cell lines to catalog molecular profiles and to assess their relation to breast cancer subtypes...
  81. ncbi A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
    Fabien Reyal
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 10:R93. 2008
    ..we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?..
  82. ncbi American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010
    ..To develop evidence-based guidelines, based on a systematic review, for endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer...
  83. ncbi Dicer, Drosha, and outcomes in patients with ovarian cancer
    William M Merritt
    University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    N Engl J Med 359:2641-50. 2008
    ..We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer...
  84. ncbi Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
    Sabine Riethdorf
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 16:2634-45. 2010
    ..This study was aimed at detecting and characterizing circulating tumor cells (CTC) before and after neoadjuvant therapy (NT) in the peripheral blood of patients with breast cancer...
  85. ncbi Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe
    Milena Sant
    Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I 20133 Milan, Italy
    Int J Cancer 106:416-22. 2003
    ..Screening for breast cancer did not seem to affect the survival patterns once stage had been taken into account...
  86. ncbi Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells
    Ubaldo E Martinez-Outschoorn
    Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Cell Cycle 9:3256-76. 2010
    ....
  87. ncbi Performance of common genetic variants in breast-cancer risk models
    Sholom Wacholder
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 5050, MSC 7244, Bethesda, MD 20892, USA
    N Engl J Med 362:986-93. 2010
    ..Genomewide association studies have identified multiple genetic variants associated with breast cancer. The extent to which these variants add to existing risk-assessment models is unknown...
  88. ncbi Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    Daniel P Silver
    Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
    J Clin Oncol 28:1145-53. 2010
    ..CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response...
  89. ncbi Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer
    Pamela J Goodwin
    Mount Sinai Hospital, 1284 600 University Ave, Toronto, Ontario M5G 1X4, Canada
    J Clin Oncol 27:3757-63. 2009
    ..Such effects are biologically plausible given the presence of vitamin D receptors in breast cancer cells, which act as nuclear transcription factors to regulate gene activity...
  90. ncbi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  91. ncbi MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer
    Guohong Hu
    Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
    Cancer Cell 15:9-20. 2009
    ..These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk...
  92. ncbi Genomic antagonism between retinoic acid and estrogen signaling in breast cancer
    Sujun Hua
    Institute for Genomics and Systems Biology and Department of Human Genetics, The University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA
    Cell 137:1259-71. 2009
    ....
  93. ncbi An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Katherine Stemke-Hale
    Department of Systems Biology, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer Res 68:6084-91. 2008
    ..The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer...
  94. ncbi A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation
    Zuoren Yu
    Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    J Cell Biol 182:509-17. 2008
    ..In turn, miR-17/20 limits the proliferative function of cyclin D1, thus linking expression of a specific miRNA cluster to the regulation of oncogenesis...
  95. ncbi Epithelial mesenchymal transition traits in human breast cancer cell lines
    T Blick
    VBCRC Invasion and Metastasis Unit, St Vincent s Institute, 9 Princes St, Fitzroy, Melbourne, VIC 3065, Australia
    Clin Exp Metastasis 25:629-42. 2008
    ..Human breast cancer cell lines with mesenchymal properties continue to hold out the promise of directing us towards key mechanisms at play in the metastatic dissemination of breast cancer...
  96. ncbi Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck
    Marta Persson
    Department of Pathology, Lundberg Laboratory for Cancer Research, the Sahlgrenska Academy at University of Gothenburg, SE 413 45 Gothenburg, Sweden
    Proc Natl Acad Sci U S A 106:18740-4. 2009
    ..Our findings also suggest that the gain-of-function activity resulting from the MYB-NFIB fusion is a candidate therapeutic target...
  97. ncbi Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer
    Nina Linder
    Research Program for Developmental and Reproductive Biology and Hospital for Children and Adolescents, Biomedicum Helsinki, University of Helsinki, Finland
    Clin Cancer Res 11:4372-81. 2005
    ....
  98. ncbi Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients
    Carol Alliot
    J Clin Oncol 23:4237-8; author reply 4238-9. 2005
  99. ncbi [Expressions of CD147 and matrix metalloproteinase-2 in breast cancer and their correlations to prognosis]
    Sheng Zhou
    Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, PR China
    Ai Zheng 24:874-9. 2005
    ..This study was to investigate the correlations of CD147 and MMP-2 expressions in tumor and adjacent tissue to metastasis, invasion, and prognosis of breast cancer...
  100. ncbi Prognostic value of ERBB family mRNA expression in breast carcinomas
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Int J Cancer 106:758-65. 2003
    ....
  101. ncbi Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast
    N Honma
    Human Tissue Research Group, Tokyo Metropolitan Institute of Gerontology, Sakaecho 35 2, Itabashi ku, Tokyo, Japan
    Histopathology 47:195-201. 2005
    ..Apocrine lesions reportedly exhibit an unusual immunohistochemical status, expressing androgen receptors (AR) instead of oestrogen receptors (ER), progesterone receptors (PR), or bcl-2. Their expression was also examined...

Research Grants87

  1. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2007
    ....
  2. CELLULAR MECHANISMS IN THE INDUCTION OF AROMATASE
    CAROLE MENDELSON; Fiscal Year: 2009
    ..We believe that this research will provide important insight into tissue-specific regulation of aromatase in normal physiology and in pathophysiologic states. ..
  3. Dissecting the Mechanisms of Tamoxifen Action
    Manohar Ratnam; Fiscal Year: 2009
    ..We propose to further investigate this and other mechanisms of tamoxifen action and in the process, to identify lead compounds whose properties are superior to that of tamoxifen. ..
  4. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
    ..This information can also provide a scientific basis to prioritize herbs for clinical trials evaluation for their ability to prevent and treat breast cancer. ..
  5. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2009
    ....
  6. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2007
    ....
  7. Molecular Epidemiology of Secondary Lung Cancer
    Peter Shields; Fiscal Year: 2007
    ..RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page .................................................................................................................................................. 1 Description, ..
  8. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2005
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  9. Protein-DNA Drug Carriers for Tumor Targeting
    Lali K Medina Kauwe; Fiscal Year: 2010
    ..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
  10. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John Katzenellenbogen; Fiscal Year: 2007
    ..These agents could improve the selection of patients for individualized and optimized hormone therapy, sparing them the morbidity associated with standard radiation and chemotherapy which would provide them with no further benefit. ..
  11. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John A Katzenellenbogen; Fiscal Year: 2010
    ..These agents could improve the selection of patients for individualized and optimized hormone therapy, sparing them the morbidity associated with standard radiation and chemotherapy which would provide them with no further benefit. ..
  12. Molecular Epidemiology of Smoking & Breast Cancer
    KATHLEEN CONWAY DORSEY; Fiscal Year: 2005
    ..If breast cancer can be attributed, in part, to cigarette smoking, then smoking prevention or cessation should reduce exposure and thus decrease the incidence of breast cancer. ..
  13. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2003
    ....
  14. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  15. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2010
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  16. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2005
    ..abstract_text> ..
  17. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2001
    ....
  18. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2004
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  19. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010
    ....
  20. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2006
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  21. Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer
    Raghuraman Kannan; Fiscal Year: 2007
    ..This has the potential to improve the early detection and diagnosis of breast cancer. ..
  22. Mechanisms of Action and Signaling by Steroid Hormone Antagonists
    DOUGLAS FALLER; Fiscal Year: 2009
    ....
  23. Mechanisms of Action and Signaling by Steroid Hormone Antagonists
    Douglas V Faller; Fiscal Year: 2010
    ....
  24. Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
    PALOMA HOBAN GIANGRANDE; Fiscal Year: 2010
    ....
  25. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2010
    ....
  26. Dissecting the Mechanisms of Tamoxifen Action
    Manohar Ratnam; Fiscal Year: 2010
    ..We propose to further investigate this and other mechanisms of tamoxifen action and in the process, to identify lead compounds whose properties are superior to that of tamoxifen. ..